Key Market Indicator:
F&G: 57
25.745,80 NASDAQ · 48.853,99 DOW · 6.933,75 S&P · 5.337,00 Gold · 69,37 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE000A11QVV0
Filter zurücksetzen
© EQS Newswire
11.07.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
Article
News Preview
PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024 HDP-101 granted Orphan Drug Designation ......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.07.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma berichtet über das erste Halbjahr 2024 und den Geschäftsverlauf
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma berichtet über das erste Halbjahr 2024 und den Geschäftsverlauf Erste vorläufige Wirksamkeitsdaten der klinischen Studie mit HDP-101 im Multiplen Myelom veröffentlicht Präsentation präklinischer und klinischer Daten der proprietären ADC-Technologieplattformen auf der AACR-Tagung 2024 HDP-101 erhält Orphan Dru......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.06.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma reports on the results of the Annual General Meeting 2024
Article
News Preview
PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 2024 Ladenburg, Germany, 21 June 2024 – Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 98,35% and 99,99%) at yesterday's ordinary virtual Annu......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
21.06.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma berichtet über die Ergebnisse der Hauptversammlung 2024
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma berichtet über die Ergebnisse der Hauptversammlung 2024 Ladenburg, 21. Juni 2024 - Die Heidelberg Pharma AG (FWB: HPHA) gab bekannt, dass die Aktionäre des Unternehmens in der gestrigen ordentlichen virtuellen Hauptversammlung folgenden Beschlussvorlagen der Verwaltung mit großer Mehrheit (zwischen 98,35 % und ......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© EQS Newswire
18.06.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma AG gibt Aktualisierung der Prognose bekannt
Article
News Preview
Ad-hoc Meldung Veröffentlichung von Insiderinformationen nach Art. 17 der Verordnung (EU) Nr. 596/2014 Heidelberg Pharma AG gibt Aktualisierung der Prognose bekannt Ladenburg, 18. Juni 2024 – Die Heidelberg Pharma AG (FWB: HPHA), ein Biotech-Unternehmen in der klinischen Phase, das innovative Antikörper-Wirkstoff-Konjugate (ADCs) entwickelt, gib......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.06.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma AG announces updated guidance
Article
News Preview
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma AG Announces Updated Guidance Ladenburg, Germany, 18 June 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its ......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.05.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma nimmt im Mai und Juni 2024 an führenden wissenschaftlichen Konferenzen teil
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma nimmt im Mai und Juni 2024 an führenden wissenschaftlichen Konferenzen teil Ladenburg, 23. Mai 2024 – Das Managementteam der Heidelberg Pharma AG (FWB: HPHA), ein klinischer Entwickler von innovativen Antikörper-Wirkstoff-Konjugaten (ADCs), wird im Mai und Juni 2024 an verschiedenen wissenschaftlichen Konferenz......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.05.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Article
News Preview
PRESS RELEASE Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.05.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Article
News Preview
PRESS RELEASE Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma AG berichtet über die ersten drei Monate 2024
Article
News Preview
Heidelberg Pharma AG berichtet über die ersten drei Monate 2024 Erste Wirksamkeitsdaten der klinischen Studie mit HDP-101 im Multiplen Myelom Prof. Dr. Andreas Pahl wird Sprecher des Vorstands Erfolgreiche Finanzierungsaktivitäten Verkauf eines Teils der zukünftigen Lizenzgebühren für Zircaix™ an HealthCare Royalty finanziert weitere Entwicklu......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Interim Management Statement on the First Three Months of 2024
Article
News Preview
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further develo......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.04.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
Article
News Preview
PRESS RELEASE Heidelberg Pharma to host R&D Webinar following novel data presented at AACR Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
05.04.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
Article
News Preview
PRESS RELEASE Heidelberg Pharma to host R&D Webinar following novel data presented at AACR Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.04.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma veranstaltet F&E-Webinar im Anschluss an Präsentation neuer Daten auf der AACR-Tagung
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma veranstaltet F&E-Webinar im Anschluss an Präsentation neuer Daten auf der AACR-Tagung Ladenburg, 5. April 2024 - Die Heidelberg Pharma AG (FWB: HPHA), ein klinischer Entwickler von innovativen Antikörper-Wirkstoff-Konjugaten (ADCs), lädt Investoren, Analysten und Medien am 23. April 2024 um 16:00 Uhr MESZ/15......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Article
News Preview
PRESS RELEASE Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has g......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma erhält Orphan Drug-Status von der FDA für ihren ATAC-Kandidaten HDP-101
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma erhält Orphan Drug-Status von der FDA für ihren ATAC-Kandidaten HDP-101 Ladenburg, 27. März 2024 - Die Heidelberg Pharma AG (FWB: HPHA), ein klinischer Entwickler von innovativen Antikörper-Wirkstoff-Konjugaten (ADCs), gab heute bekannt, dass sie von der amerikanischen Zulassungsbehörde (Food and Drug Administr......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet über erfolgreichen Geschäftsverlauf 2023
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet über erfolgreichen Geschäftsverlauf 2023 Erste Wirksamkeitsdaten der klinischen Studie mit HDP-101 im Multiplen Myelom Erweiterung der ADC-Technologieplattform um weitere Wirkstoffe Neues Vorstandsteam Erfolgreiche Finanzierungsaktivitäten; Umsatzerlöse und sonstige Er......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
Article
News Preview
PRESS RELEASE Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing activities; sales revenue and other i......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma erhält nicht rückzahlbare Vorabzahlung nach erfolgreichem Vollzug der Vereinbarung mit HealthCare Royalty über den Verkauf von Lizenzgebühren
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma erhält nicht rückzahlbare Vorabzahlung nach erfolgreichem Vollzug der Vereinbarung mit HealthCare Royalty über den Verkauf von Lizenzgebühren Ladenburg, 19. März 2024 - Die Heidelberg Pharma AG (FWB: HPHA), ein klinischer Entwickler von innovativen Antikörper-Wirkstoff-Konjugate (ADCs), gab heute den formellen A......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Article
News Preview
PRESS RELEASE Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today ann......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma startet Kohorte 6 der Phase I/IIa-Studie im Multiplen Myelom mit dem ATAC-Kandidaten HDP-101
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma startet Kohorte 6 der Phase I/IIa-Studie im Multiplen Myelom mit dem ATAC-Kandidaten HDP-101 Daten der Dosiseskalation mit HDP-101 zeigen in ersten Patienten der Kohorte 5 ein objektives Ansprechen und partielle Remissionen Erweiterte Kohorte 6 mit geändertem Protokoll umfasst Dosisoptimierung, einschließlich d......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Article
News Preview
PRESS RELEASE Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5 Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms a......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
EQUITS GmbH: Heidelberg Pharma AG | Rating: Kaufen
Article
News Preview
Original-Research: Heidelberg Pharma AG - von EQUITS GmbH Einstufung von EQUITS GmbH zu Heidelberg Pharma AG Unternehmen: Heidelberg Pharma AG ISIN: DE000A11QVV0 Anlass der Studie: Research Update Empfehlung: Kaufen seit: 07.03.2024 Kursziel: 8,90 Kursziel auf Sicht von: 12 Monate Letzte Ratingänderung: Analyst: Thomas Schiessle EQUI.TS GmbH (07.......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma präsentiert erste Wirksamkeitsdaten zu HDP-101 und Daten der proprietären ADC-Technologieplattform auf der AACR-Tagung 2024
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma präsentiert erste Wirksamkeitsdaten zu HDP-101 und Daten der proprietären ADC-Technologieplattform auf der AACR-Tagung 2024 Ladenburg, 6. März 2024 – Die Heidelberg Pharma AG (FWB: HPHA), ein Biotech-Unternehmen in der klinischen Phase, das innovative Antikörper-Wirkstoff-Konjugate (ADCs) entwickelt, wird auf de......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Article
News Preview
PRESS RELEASE Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024 Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its P......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Article
News Preview
PRESS RELEASE Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranche......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma schließt Finanzierungsvereinbarung mit HealthCare Royalty in Höhe von bis zu 115 Millionen USD ab
Article
News Preview
PRESSEMITTEILUNG Heidelberg Pharma schließt Finanzierungsvereinbarung mit HealthCare Royalty in Höhe von bis zu 115 Millionen USD ab HealthCare Royalty erwirbt das Recht auf Lizenzzahlungen aus den weltweiten Verkäufen von Telix Pharmaceuticals' bildgebendem Diagnostikum ZircaixTM (TLX250-CDx) Heidelberg Pharma hat Anspruch auf bis zu 115 Mio.......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Article
News Preview
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) H......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
ISIN: DE000A11QVV0
Heidelberg Pharma AG
HPHA
LISTED
XETR
Heidelberg Pharma schließt Finanzierungsvereinbarung mit HealthCare Royalty in Höhe von bis zu 115 Millionen USD ab
Article
News Preview
Ad-hoc Meldung Veröffentlichung von Insiderinformationen nach Art. 17 der Verordnung (EU) Nr. 596/2014 Heidelberg Pharma schließt Finanzierungsvereinbarung mit HealthCare Royalty in Höhe von bis zu 115 Millionen USD ab HealthCare Royalty erwirbt das Recht auf Lizenzzahlungen aus den weltweiten Verkäufen von Telix Pharmaceuticals' bildgebendem D......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 29.01.2026, Calendar Week 05, 29th day of the year, 336 days remaining until EoY.